TY - JOUR
TI - Metabolic Syndrome and Risks of Colon and Rectal Cancer: The European
Prospective Investigation into Cancer and Nutrition Study
AU - Aleksandrova, Krasimira
AU - Boeing, Heiner
AU - Jenab, Mazda and
AU - Bueno-de-Mesquita, H. Bas
AU - Jansen, Eugene
AU - van Duijnhoven, Franzel
AU - J. B.
AU - Fedirko, Veronika
AU - Rinaldi, Sabina
AU - Romieu, Isabelle and
AU - Riboli, Elio
AU - Romaguera, Dora
AU - Overvad, Kim
AU - Ostergaard, Jane
AU - Nautrup
AU - Olsen, Anja
AU - Tjonneland, Anne
AU - Boutron-Ruault,
AU - Marie-Christine
AU - Clavel-Chapelon, Francoise
AU - Morois, Sophie and
AU - Masala, Giovanna
AU - Agnoli, Claudia
AU - Panico, Salvatore
AU - Tumino,
AU - Rosario
AU - Vineis, Paolo
AU - Kaaks, Rudolf
AU - Lukanova, Annekatrin and
AU - Trichopoulou, Antonia
AU - Naska, Androniki
AU - Bamia, Christina and
AU - Peeters, Petra H.
AU - Rodriguez, Laudina
AU - Buckland, Genevieve and
AU - Sanchez, Maria-Jose
AU - Dorronsoro, Miren
AU - Huerta, Jose-Maria and
AU - Barricarte, Aurelio
AU - Hallmans, Goran
AU - Palmqvist, Richard
AU - Khaw,
AU - Kay-Tee
AU - Wareham, Nicholas
AU - Allen, Naomi E.
AU - Tsilidis,
AU - Konstantinos K.
AU - Pischon, Tobias
JO - Cancer Prevention Research
PY - 2011
VL - 4
TODO - 11
SP - 1873-1883
PB - AMER ASSOC CANCER RESEARCH
SN - 1940-6207, 1940-6215
TODO - 10.1158/1940-6207.CAPR-11-0218
TODO - null
TODO - Metabolic syndrome (MetS) is purportedly related to risk of developing
colorectal cancer; however, the association of MetS, as defined
according to recent international criteria, and colorectal cancer has
not been yet evaluated. In particular, it remains unclear to what extent
the MetS components individually account for such an association. We
addressed these issues in a nested case-control study that included
1,093 incident cases matched (1: 1) to controls by using incidence
density sampling. Conditional logistic regression was used to estimate
relative risks (RR) and 95% CIs. MetS was defined according to the
criteria of the National Cholesterol Education Program/Adult Treatment
Panel III (NCEP/ATPIII), the International Diabetes Federation (IDF),
and the 2009 harmonized definition. Among individual components,
abdominal obesity (RR = 1.51; 95% CI: 1.16-1.96) was associated with
colon cancer, whereas abnormal glucose metabolism was associated with
both colon (RR = 2.05; 95% CI: 1.57-2.68) and rectal cancer (RR = 2.07;
95% CI: 1.45-2.96). MetS, as defined by each of the definitions, was
similarly associated with colon cancer (e. g., RR = 1.91; 95% CI:
1.47-2.42 for MetS by NCEP/ATPIII), whereas MetS by NCEP/ATPIII, but not
IDF or harmonized definition, was associated with rectal cancer (RR =
1.45; 95% CI: 1.02-2.06). Overall, these associations were stronger in
women than in men. However, the association between MetS and colorectal
cancer was accounted for by abdominal obesity and abnormal glucose
metabolism such that MetS did not provide risk information beyond these
components (likelihood ratio test P = 0.10 for MetS by NCEP/ATPIII).
These data suggest that simple assessment of abnormal glucose metabolism
and/or abdominal obesity to identify individuals at colorectal cancer
risk may have higher clinical utility than applying more complex MetS
definitions. Cancer Prev Res; 4(11); 1873-83. (C) 2011 AACR.
ER -